Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970.